Introduction {#Sec1}
============

The coronavirus disease 19 (COVID-19) is a global epidemic with high morbidity and mortality. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new strain isolated from the Huanan Seafood Market, Wuhan, China in December 2019 (Fox [@CR32]; Khan et al. [@CR52]). Horseshoe bat is a primary reservoir, but the intermediate source of origin and transfer to humans is fully understood (Guo et al. [@CR41]; Singhal [@CR95]). Human coronaviruses (*Coronaviridae* family; *Nidovirales* order) can cause respiratory, gastrointestinal, hepatic, and central nervous system diseases. SARS-CoV-2 is the seventh coronavirus of which two α-coronaviruses (HCoV-229E and HCoV-NL63) and two β-coronaviruses (HCoV-OC43 and HCoV-HKU1) are causing only mild self-limiting upper respiratory diseases. SARS-CoV-2, SARS-CoV, and MERS-CoV can cause severe diseases (Li et al. [@CR58]). Human-to-human contact and travel-related cases are transmission mechanisms for the SARS-CoV-2 outbreak (Ralph et al. [@CR86]). The fecal--oral transmission is a possible transmission mechanism of SARS-CoV-2 infection in children (Zhang et al. [@CR116]). SARS-CoV-2 is sensitive to heat and UV rays and can be effectively destroyed with the use of 75% ethanol, *p*-acetic acid, and chlorine-containing disinfectants (Zhou et al. [@CR119]).

On 11 March 2020, the World Health Organization (WHO) declared the outbreak a pandemic. As of 20 July 2020, 14.6 million cases have been confirmed in more than 210 countries, with 608k deaths. The United States, Spain, Italy, and Germany have registered more cases than China, where the outbreak started (<https://www.worldometers.info/coronavirus/>). Consequently, the WHO declared a state of global health emergency to coordinate scientific and medical efforts to rapidly develop a cure for patients (Sohrabi et al. [@CR96]). The development of more targeted inhibitors is highly desirable, but no effective antiviral drugs or vaccines available to date (Li et al. [@CR57]). The source of origin, transmission, and pathogenesis mechanisms of this virus are not yet known. It hampers further investigation of safe and valuable antiviral medications. The massive research works on its genomics perspectives provide a warrant to discover antivirals against COVID-19 infectivity.

Genomic insights of SARS-CoV-2 {#Sec2}
==============================

Genome structure {#Sec3}
----------------

SARS-CoV-2 belongs to the *Sarbecovirus* subgenus (*β-Coronavirus* genus). It is an enveloped virus containing a single positive‐stranded RNA (Chan et al. [@CR17]; Lu et al. [@CR66]; Licastro et al. [@CR62]; Yu et al. [@CR113]; Zhou et al. [@CR120], [@CR119]). The first genome sequence (accession: NC_045512.2) was completed for SARS-CoV-2 Wuhan-Hu-1 isolated from Wuhan, Hubei province, China (Wu et al. [@CR106]). Continuous genome sequencing attempts of different laboratories have been produced 930 GenBank sequences and 288 next-generation sequences to date. The genome size of this virus is 29.9 kb with 11 open reading frames (Orfs). ORF1ab (266--21555 nts.) encodes replicase polyprotein 1ab. After cleaved by two proteases, ORF1ab (266--13483 nts.) encodes replicase polyprotein 1a with multiple functions. Gene-coding proteins are organized as 5′-leader-UTR-replicase-ORFab-S (spike)-E (envelope)-M (membrane)-N (nucleocapsid)-3′UTR-poly (A) tail-3′-UTR end (Kandeel et al. [@CR49]; Zhou et al. [@CR120]) (Table [1](#Tab1){ref-type="table"}).Table 1Genomic information of emerging SARS-CoV-2 Wuhan-Hu-1 isolate (Accession: NC_045512.2)Locus tagGeneStartStopStrandLengthProtein NameGene IDProtein IDGU280_gp01ORF1ab26621555+7096ORF1ab polyprotein43740578YP_009724389.1GU280_gp01ORF1ab26613483+4405ORF1a polyprotein43740578YP_009725295.1GU280_gp02S2156325384+1273Surface glycoprotein43740568YP_009724390.1GU280_gp03ORF3a2539326220+275ORF3a protein43740569YP_009724391.1GU280_gp04E2624526472+75Envelope protein43740570YP_009724392.1GU280_gp05M2652327191+222Membrane glycoprotein43740571YP_009724393.1GU280_gp06ORF62720227387+61ORF6 protein43740572YP_009724394.1GU280_gp07ORF7a2739427759+121ORF7a protein43740573YP_009724395.1GU280_gp08ORF7b2775627887+43ORF7b43740574YP_009725296.1GU280_gp09ORF82789428259+121ORF8 protein43740577YP_009724396.1GU280_gp10N2827429533+419Nucleocapsid phosphoprotein43740575YP_009724397.2GU280_gp11ORF102955829674+38ORF10 protein43740576YP_009725255.1GU280_gp01ORF1ab1347613503+27Coronavirus frameshifting stimulation element stem-loop 1GU280_gp01ORF1ab1348813542+54Coronavirus frameshifting stimulation element stem-loop 2GU280_gp11ORF102960929644+35Coronavirus 3′ UTR pseudo-knot stem-loop 1GU280_gp11ORF102962929657+28Coronavirus 3′ UTR pseudo-knot stem-loop 23′UTR stem-loop motif^a^2967529903+228Coronavirus 3′ stem-loop 2-like motif (s2m)2972829768+40Coronavirus 3′ stem-loop 2-like motif (s2m)^a^Coordinates 29740:29758 form a noncanonical C: T base pair, but the homologous positions form a highly conserved C: G base pair in other viruses, including SARS (NC_004718.3)

The ORF1ab gene encodes a polyprotein consisting of 15 nonstructural proteins (Nsp1-16) (Fig. [1](#Fig1){ref-type="fig"}). This polyprotein is auto-proteolytically cleaved into multiple enzymes that form replicase-transcriptase machinery consisting of RNA-dependent RNA polymerase (RdRp), helicase, 3′--5′ exonuclease, endoRNAse and 2′-O-ribose methyltransferase. These enzyme components are essential to viral genome replication and nucleic acid metabolism (Gordon et al. [@CR39]). The replicase-transcriptase system assembles at the host endoplasmic reticulum where structural proteins assembled to make essential cellular components (capsid).Fig. 1Genomic organization and gene neighborhood (**a**) of emerging SARS-CoV-2 Wuhan-Hu-1 isolate. The function of ORF1ab gene-coding proteins is presented in (**b**)

A nonstructural protein 1 (Nsp1) is a host translation inhibitor that facilitates efficient viral gene expression in infected cells and evasion from the host immune response by interacting with the 40S ribosomal subunit. ORF1ab gene contains coronavirus frameshifting stimulation element stem-loop 1 and 2 in the position of 13476--13503 and 13488--13542 nucleotides, respectively. ORF10 gene harbors coronavirus 3′ UTR pseudo-knot stem-loop 1 (29609--29644 nucleotides) and 2 (29629--29657 nucleotides). The size of the stem-loop structure is ranged from 27 to 54 nucleotides. The genomic position 29740--29758 nucleotides form a noncanonical C: T base pair. The homologous positions form a highly conserved C: G base pair (Ashour et al. [@CR5]; Kandeel et al. [@CR49]; Li et al. [@CR60]).

Genome evolution {#Sec4}
----------------

The genome of SARS-CoV-2 is about 82%, 96%, and 86.9% identical to the SARS-CoV, bat-CoV-RaTG13, and bat-SL-CoVZC45, respectively (Zhou et al. [@CR119]). However, the SARS-CoV-2 genome is genetically distinct from SARS-CoV and has a relatively long branch length to the bat-CoV-RaTG13 and bat-SL-CoVZXC21. SARS-CoV-2 genome is 99.98% identical across the SARS-CoV-2 genomes obtained from different patients (Lu et al. [@CR66]). The genome-coding potential is closely related to those of the bat, civet, and HCoVs (Chan et al. [@CR17]). Genetic recombination events are complex more likely occurring in bat-CoV-RaTG13 and bat-SL-CoVZXC21than in SARS-CoV-2 (Lu et al. [@CR66]; Paraskevis et al. [@CR78]). A phylogenetic network analysis of 160 complete SARS-CoV-2 genomes found three central mutational variants distinguished by amino acid changes. Accordingly, it has classified into A, B, and C ancestral types. The synonymous mutations T29095C and T8782C are identified in type A and type B, respectively. The non-synonymous mutations C28144T (Leu to Ser) and G26144T (Gly to Val) are detected in type B and type C, respectively (Forster et al. [@CR31]). Therefore, the genetic diversity of SARS-CoV-2 has been expanded in human hosts due to the establishment of hyper-variable genomic hotspot its population (Wen et al. [@CR105]).

Hyper-variable genomic hotspots {#Sec5}
-------------------------------

Some mutational hotspots identified from structural and nonstructural genes had deleterious effects on the functional evolution of coding proteins, host specificity, and infectivity of SARS-CoV-2 (Li et al. [@CR59]; Phan [@CR80]). SARS-CoV-2 mutational hotspots are located at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403, and 28881, where a mutation at position 14408 is adjacent to the drugs targeting RdRp hydrophobic clef (Pachetti et al. [@CR77]). The spike glycoprotein of this virus contains a receptor-binding domain (RBD), which shares only a 40% amino acid identity with other SARS-related coronaviruses (Chan et al. [@CR17]). It has the non-synonymous mutation sites that slow down the development of therapeutics apart from biologics and macrocyclic peptides (Morse et al. [@CR71]). The RBD has three possible mutation hotspots include D614G, G476S, and V483A of which V483A repeated more frequently followed by G476S. A variant D614G could bring a potentially crucial change in a protein sequence due to aspartic acid is a negatively charged and acidic amino acid compared to glycine (Banerjee et al. [@CR8]).

The envelope and nucleocapsid proteins contain two evolutionarily conserved regions with a sequence identity of 89--96% to the SARS-CoV. ORF3b and ORF8 proteins are structurally different from those of SARS-CoV (Zhou et al. [@CR119]). The endosome-associated-protein-like domain in sp2 protein had a stabilizing mutation. The Nsp3 protein is imposed by a destabilizing mutation. It suggests a possible mechanism of differentiating SARS-CoV-2 from SARS-related coronaviruses (Angeletti et al. [@CR3]). The hyper-variable genomic hotspot (Ser/Lue) is found in ORF8 protein (Ceraolo and Giorgi [@CR16]). The mutations identified in Nsp1, Nsp3, and Nsp15 might facilitate human adaptation and infection (Wen et al. [@CR105]). The intrinsic disorder predisposition in the nonstructural proteins during evolution may also provide important information to explore its infectivity (Fahmi et al. [@CR30]; Goh et al. [@CR38]). Since, finding mutational variants in viral target proteins are important to assess possible drug-resistance phenotypes, leading to modulate the clinical presentation of the COVID-19 worldwide.

The high-frequency SNP mutation sites and hyper-variable hotspots are important for designing a COVID-19 vaccine and rapid detection of different genotypes of SARS-CoV-2. Most recently, a genotypic method has been established for monitoring and tracing SARS-CoV-2 mutations (Yin 2020). The 2019 Novel Coronavirus Resource (2019nCoVR, <https://bigd.big.ac.cn/ncov>) was built for studies on viral taxonomy, genome evolution, molecular diagnosis, and drug development (Zhao et al. [@CR118]). The Genome Detective Coronavirus Typing Tool has been developed for accurate tracking of new viral mutations in SARS-CoV-2 genome sequences (Cleemput et al. [@CR24]). These resources would allow us to agitate the drug discovery process for the COVID-19 infectivity.

Pathogenomics {#Sec6}
-------------

The functions of structural and nonstructural proteins are associating with pathophysiology and virulence of SARS-CoV-2. The envelope protein has a critical role in viral assembly and releases exerting viral pathogenicity and other nonstructural proteins have not yet been described (Wang et al. [@CR104]). The surface glycoprotein contains the S2 subunit comprising a fusion peptide, a transmembrane domain, and a cytoplasmic domain (Rabaan et al. [@CR85]). These domains are guiding the link to host receptors. An in silico mutational study suggests a higher affinity of the SARS-Cov-2 spike protein favorable to the human ACE2 receptor, compared to the Bat-CoV spike protein (Hussain et al. [@CR45]; Ortega et al. [@CR75]). The N82 in ACE2 is closer contact with spike protein than M82 in human ACE2 (Luan et al. [@CR67]). Structural genomics analysis on spike protein provides important insights to design an optimized ACE2 for SARS-CoV-2 infection. The structural variations in spike protein (Ser19Pro; Glu329Gly) and the transmembrane helical segments of nsp2 and nsp3 proteins (Ser723Gly; Pro1010Iso) may determine the host specificity of SARS-CoV-2. Such mutation hotspots in spike protein and nonstructural proteins of SARS-CoV-2 might affect molecular recognition and specificity of antivirals or vaccigenic candidates. These mutations can also influence the binding efficiency of PCR primers or probes during the molecular diagnosis of clinical samples. Consequently, evidence of such mutation hotspots could explain how SARS-CoV-2 has a mechanism for disease relapses in a host (Angeletti et al. [@CR3]; Korber et al. [@CR54]).

SARS-CoV-2 infection is capable of producing an excessive immune reaction in the host. The IL-6 is produced during infection by activated leukocytes and acts on a large number of cells and also stimulates the production of acute-phase proteins important to the thermoregulation. Subsequently, B lymphocyte differentiation has been elevated for inhibition of further virus replication in a host (Cascella et al. [@CR15]; Prompetchara et al. [@CR84]; Rabaan et al. [@CR85]). SARS-CoV accessory protein ORF6 antagonizes the antiviral activity of the STAT1 transcription factor by sequestering IMPα/β1 on the rough ER/Golgi membrane (Frieman et al. [@CR33]). Ivermectin is the US Food and Drug Administration (FDA)-approved broad-spectrum antiparasitic agent and HIV-1 integrase, which reported as an effective nuclear transport inhibitor against SARS-CoV-2 in vitro (Caly et al. [@CR13]). The density of the expression levels of ACE2 in neurological tissue also suggests the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19 (Baig et al. [@CR7]).

SARS-CoV-2 requires host cellular factors for successful replication during infection. The mechanisms of its infection can be elucidated with a systematic analysis of virus-host protein--protein interactions (PPIs) (Bösl et al. [@CR11]; Rothan and Byrareddy [@CR90]). It is hypothesized that a host protein that functionally associates with this virus is localized in the corresponding sub-network within the comprehensive human interactome network. The host dependency factors mediating virus infection and effective molecular targets should be identified for developing broad-spectrum antiviral drugs for COVID-19. The previous virus-host proteome interaction studies identified the key host-specific proteins and interactions pathways including DNA replication, epigenetic and gene expression regulators, vesicle trafficking, lipid modification, ubiquitin ligases, and nuclear transport machinery (Table [2](#Tab2){ref-type="table"}). Orf10 of SARS-CoV-2 has interacted with the human ubiquitin system with multiple members of the Culin-2 E3 Ligase complex (Gordon et al. [@CR39]).Table 2SARS-CoV-2 proteins and human proteome interactive pathwaysSARS-CoV-2 proteinsHuman proteome interactive pathwaysNsp1DNA replicationNsp5, Nsp8, Nsp13, EEpigenetic and gene expression regulatorsNsp6, Nsp7, Nsp10, Nsp13, Nsp15, Orf3a, E, Orf8Vesicle traffickingSpikeLipid modificationNsp8, NRNA processing and regulationOrf10Ubiquitin ligasesNsp8, Nsp13, N, Orf9bHost signalingNsp9, Nsp15, Orf6Nuclear transport machineryNsp1, Nsp13CytoskeletonNsp4, Nsp8, Orf9cMitochondriaNsp9Extracellular matrixSource: Gordon et al. ([@CR39])

Structural genomics on drug targets {#Sec7}
===================================

Structural genomics analysis reveals the SARS-CoV-2 genome consisting of four structural proteins (S--E--M--N) and two nonstructural proteins (main protease and RdRp) (Kandeel et al. [@CR49]). Spike, main protease (3CLpro), papain-like protease (PLpro), and RdRp are promising therapeutic targets for SARS-CoV infections (Li and De Clercq [@CR56]; Yoshimoto [@CR112]). The structural and functional characteristics of these proteins are summarized here and represented in Table [3](#Tab3){ref-type="table"}. Viral exoribonuclease greatly affects the cell's transcriptome by RNA processing and degradation.Table 3Crystallographic structures information on anti-SARS-CoV-2 drugs targeting proteinsName of protein's structurePDB IDRelease dateResolution (Ã)Residue3C-like protease (apo)6M2Q15-04-20201.73063C-like protease-5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one6M2N15-04-20202.19812243C-like proteinase-K366WTJ20-05-20201.93063C-like proteinase-UED6WTK20-05-20202306Main protease7BRO13-05-20202307Main protease (structural plasticity)6WQF06-05-20202.3306Main protease (apo)6M0311-03-20202306Main protease (free)6Y2E04-03-20201.75306Main protease (monoclinic)-alpha-ketoamide 13b6Y2F04-03-20201.95306Main protease (orthorhombic)-alpha-ketoamide 13b6Y2G04-03-20202.2612Main protease (reaction state)-alpha-ketoamide 13b6Y7M18-03-20201.9306Main protease (unliganded active site)6Y8411-03-20201.39306Main protease (unliganded active site)6YB725-03-20201.25306Main protease-11a6LZE29-04-20201.505306Main protease-11b6M0K29-04-20201.504307Main protease-2-Methyl-1-tetralone6YNQ29-04-20201.8306Main protease-AZD6482.6YVF20-05-20201.6306Main protease-Boceprevir6WNP06-05-20201.443306Main protease-Carmofur7BUY29-04-20201.6306Main protease-GC3767BRR13-05-20201.4614Main protease-GC-3766WTT20-05-20202.15930Main protease-HU57BRP13-05-20201.8614Main protease-Leupeptin6YZ620-05-20201.7310Main protease-N36LU705-02-20202.16312Main protease-N37BQY22-04-20201.7312Main protease-Pyrithione zinc6YT806-05-20202.05306Main protease-X776W6325-03-20202.1306NSP10-NSP16 complex6W7525-03-20201.951886NSP10-NSP16 methyltransferase-Sinefungin6YZ113-05-20202.4422NSP15 Endoribonuclease6VWW04-03-20202.2742NSP15 Endoribonuclease-Citrate6W0111-03-20201.9742NSP15 Endoribonuclease-Tipiracil6WXC20-05-20201.85700NSP15 Endoribonuclease-Uridine-5′-Monophosphate6WLC29-04-20201.82700NSP16--NSP10 complex6W4H18-03-20201.8443NSP16 and NSP10 methyltransferase-stimulatory factor complex6W6125-03-20202439NSP16--NSP10 ternary complex6WKS06-05-20201.8437NSP16--NSP10 heterodimer-7-Methyl-GpppA and S-adenosyl-L-homocysteine6WQ306-05-20202.1443NSP16--NSP10 heterodimer-7-Methyl-GpppA and S-adenosyl-L-homocysteine6WRZ13-05-20202.25443NSP16--NSP10 heterodimer-7-Methyl-GpppA and S-Adenosylmethionine6WVN13-05-20202443NSP16--NSP10 heterodimer-S-Adenosyl-L-homocysteine6WJT22-04-20202886NSP16--NSP10 heterodimer-Sinefungin6WKQ29-04-20201.98886NSP3 ADP-ribose phosphatase6VXS04-03-20202.03340NSP3 ADP-ribose phosphatase (apo)6WEN15-04-20201.35170NSP3 ADP-ribose phosphatase-ADP-ribose6W0211-03-20201.5340NSP3 ADP-ribose phosphatase-AMP6W6Y25-03-20201.451340NSP3 ADP-ribose phosphatase-MES6WCF15-04-20201.065170NSP3 Macro X domain6WEY29-04-20200.95172NSP3 macrodomain-ADP-ribose6WOJ06-05-20202.2704NSP3 macrodomain-ADP-ribose6YWL06-05-20202.5865NSP3 macrodomain-HEPES6YWK06-05-20202.2865NSP3 macrodomain-MES6YWM06-05-20202.16519NSP7 and NSP8 C-terminal domain-Cofactor complex6WIQ22-04-20202.85208NSP7 and NSP8 C-terminal domain-Cofactor complex6WQD06-05-20201.95416NSP7 and NSP8 C-terminal domain-Cofactor complex6WTC13-05-20201.85416NSP7-NSP8 complex6YHU29-04-20202376NSP9 RNA-binding protein6W4B18-03-20202.95234NSP9 RNA-replicase6WXD20-05-20202232NSP9 RNA-replicase-peptide6W9Q08-04-20202.05133Nucleocapsid phosphoprotein6VYO11-03-20201.7512Nucleocapsid phosphoprotein C-terminal dimerization domain6WJI22-04-20202.052726Nucleocapsid phosphoprotein C-terminal dimerization domain6YUN20-05-20201.44270Nucleocapsid phosphoprotein RNA-binding domain (monoclinic)6WKP29-04-20202.67512Nucleocapsid protein C-terminal domain7C2220-05-20202480Nucleocapsid protein N-terminal RNA-binding domain6M3M18-03-20202.7544ORF7A accessary protein6W3729-04-20202.967Papain-like protease6W9C01-04-20202.7951Papain-like protease C111S mutant6WRH06-05-20201.6318Papain-like protease C111S mutant-mISG156YVA13-05-20203.18476Papain-like protease-VIR2506WUU20-05-20202.791324Papain-like protease-VIR2516WX420-05-20201.655331Spike protein S2 subunit (post fusion core)6LXT26-02-20202.9792Spike protein HR2 domain6LVN26-02-20202.47144Spike protein RBD-ACE26VW104-03-20202.681628Spike protein RBD-ACE26LZG18-03-20202.5805Spike protein RBD-ACE26M0J18-03-20202.45832Spike protein RBD-CR3022 Fab6W4125-03-20203.084674Spike protein RBD-CR3022 Fab6YLA15-04-20202.421324Spike protein RBD-CR3022 Fab (crystal form)6YM029-04-20204.36661Spike protein RBD-VHH-72 Fab6WAQ01-04-20202.2636Spike protein S2 subunit RBD-B38 Fab7BZ513-05-20201.84669

Spike glycoprotein {#Sec8}
------------------

SARS-CoV-2 infects ciliated bronchial epithelial cells and type-II pneumocytes where an envelope-anchored spike protein binds to a host receptor angiotensin-converting enzyme 2 (ACE2) (Lan et al. [@CR55]; Li et al. [@CR61]; Zhou et al. [@CR120]). The spike protein is cleaved via acid-dependent proteolysis by furin protease into an N-terminal S1 subunit (residue 14--685) and a C-terminal S2 region (residue 686--1273), followed by fusion of the viral envelop to the cellular membranes (Coutard et al. [@CR26]). It has a functional polybasic (furin) cleavage site at the S1--S2 boundary through the insertion of 12 nucleotides. Both the polybasic cleavage site and the three adjacent predicted O-linked glycans are unique to SARS-CoV-2. Insertion of a furin cleavage site at the S1--S2 junction enhances cell--cell fusion without affecting viral entry (Hasan et al. [@CR44]; Rabaan et al. [@CR85]; Walls et al. [@CR101]).The function of the predicted O-linked glycans could create a 'mucin-like domain' that helps SARS-CoV-2 to utilize mucin-like domains as glycan shields involved immunoevasion (Bagdonaite and Wandall [@CR6]).

Crystallographic studies reveal the structure of the six-helical bundle core of the HR1 and HR2 domains in the S2 subunit (Fig. [2](#Fig2){ref-type="fig"}). It has a defined RBD in an N-terminal S1 subunit that specifically recognizes its receptor in humans (Lan et al. [@CR55]; Lu et al. [@CR66]; Xia et al. [@CR107]). The RBD contains a core structure and a receptor-binding motif (RBM) that binds to the ACE2 receptor-binding region, integrin (Cagliani et al. [@CR12]; Sigrist et al. [@CR94]). The involvement of glucose-regulated protein-78 and RBD are important in recognition of the host ACE2 receptor. The binding is more favorable between regions III (C391--C525) and IV (C480--C488) of the spike protein and glucose-regulated protein-78 (Ibrahim et al. [@CR46]).Fig. 23D structural view for the representation of SARS-CoV-2 spike glycoprotein (**a**) in complex with ACE2 (**b**) and sodium-dependent neutral amino acid transporter (**c**)

The binding efficiency of RBD on ACE2 can be enhanced by the presence of specific amino acids at the 442, 472, 479, 480, and 487 positions. Gln493 and Asn501 residues in the RBM provide possible interactions with ACE2. SARS-CoV-2 has acquired some capacity for human cell infection and human-to-human transmission by super binding affinity of Gln493 and Asn501 residues in RBM with ACE2 (Wan et al. [@CR102]). It is most likely the result of natural selection on a human (Andersen et al. [@CR2]; Zhang et al. [@CR117]).

The RBM recognizes directly the integrins of the ACE2 receptor-binding region and RBD has a critical impact on the cross-reactivity of neutralizing antibodies. It suggests a promising therapeutic target. EK1C4 is the most potent pan-coronavirus fusion inhibitor targeting its spike protein (Xia et al. [@CR107]). ACE2 blocker is repurposed to control COVID-19 from gaining entry into the host cell (Phadke and Saunik [@CR79]). Therefore, it is still necessary to develop novel monoclonal antibodies targeting RBD and fusion inhibitors targeting the S2 subunit, which will be effective therapeutics against COVID-19 (Sigrist et al. [@CR94]; Shanmugaraj et al. [@CR92]; Tian et al. [@CR98]).

RNA‐dependent RNA polymerase {#Sec9}
----------------------------

The RdRp is a crucial viral enzyme in the life cycle of RNA viruses that catalyzes the replication of RNA from the RNA template. ORF1ab gene-encoding polyprotein can be cut by the main protease of the virus to form RdRp and helicase (Yang and Wang [@CR110]). The structural genomics studies found the active site of this enzyme highly conserved with two successive and surface-accessible aspartates in a beta-turn structure (Elfiky [@CR28], [@CR29]). It has conserved polymerase motifs A--G in the palm domain having an active site chamber. It has a unique N-terminal β-hairpin at its N-terminal (Gao et al. [@CR36]). Crystallographic structure (PDB ID: 6M71) and homology model of this enzyme offer a way to find efficient RdRp inhibitors to treat COVID-19 (Elfiky [@CR28]) (Fig. [3](#Fig3){ref-type="fig"}). Molecular docking studies found theaflavin as a potential RdRp inhibitor that binds to the catalytic pocket of RdRp (−9.11 kcal/mol) (Lung et al. [@CR69]). Hydrophobic and π-cation interactions are contributed significantly to binding between theaflavin and Arg553 side chain of RdRp (Lung et al. [@CR69]). Several rapid drug repurposing efforts have been made for the identification of promising antiviral drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) against COVID-19 (Elfiky [@CR29]; Gordon et al. [@CR39]; Reina [@CR88]; Shah et al. [@CR91]; Wang et al. [@CR103]). Hence, drug repurposing strategy is an effective one to discover the FDA-approved drugs targeting RdRp.Fig. 33D structural view for the representation of SARS-CoV-2 proteins targeting for drug designing process

Papain-like protease {#Sec10}
--------------------

This enzyme helps to assemble a virally induced cytoplasmic double-membrane vesicle along with Nsp4 and then cleaves at the N-terminus of the replicase polyprotein for viral replication. It also removes ubiquitin and IFN-stimulated gene 15 from cellular proteins through the processing of Lys-48- and Lys-63-linked polyubiquitin chains (Clasman et al. [@CR23]). It can be antagonized IFN-I induced innate immunity and also prevented host NF-kappa-B signaling by blocking subsequent nuclear translocation of host IFN regulatory factor-3. The structural information of this enzyme provides new insights as a valuable target for drug repositioning to treat SARS-CoV-2 infections (Wu et al. [@CR106]). Some potential inhibitors targeting papain-like protease are identified by using a virtual screening approach using the CDOCKER program (Ma et al. [@CR70]).

Main protease {#Sec11}
-------------

The main protease (3CL-PRO) is a cysteine protease responsible for the processing of ORF1ab polyprotein at 11 sites. It recognizes a motif sequence \[ILMVF\]-Q-\[SGACN\] in the ORF1ab polyprotein and also binds an ADP-ribose-1-phosphate moiety. As shown in Fig. [3](#Fig3){ref-type="fig"}, a crystal structure of this enzyme contains six-stranded antiparallel β-barrels harboring a substrate-binding site located between chymotrypsin-3C protease-like domains I and picornavirus 3C protease-like domains II (Zhang et al. [@CR115]). Like SARS-CoV, a globular cluster of five helices is located in domain III (residues 198--303) regulating the dimerization process through a salt-bridge interaction between Glu290 of one protomer and Arg4 of the other (Shi and Song [@CR93]; Chen et al. [@CR22]; Chatterjee et al. [@CR19]). Covalent main protease inhibitors are targeting the catalytic dyad (His41 and Cys145) of this enzyme (Paasche et al. [@CR76]; Li et al. [@CR59]). The α-ketoamide 13b, the main protease inhibitor binds to the shallow substrate-binding site. A thiohemiketal is formed in a reversible reaction through the nucleophilic attack of the catalytic Cys145 onto the α-keto group of α-ketoamide 13b (Zhang et al. [@CR115]).

Several inhibitors include paritaprevir, raltegravir, velpatasvir, ledipasvir, vinyl sulfone, lopinavir, and ritonavir are identified as repurposable drugs for inhibiting 3C-like protease of SARS-CoV-2 (Chen et al. [@CR22]; Cao et al. [@CR14]; Morse et al. [@CR71]; Nutho et al. [@CR74]; Khan et al. [@CR51]). The FDA has already approved these antivirals for the systematic treatment of chronic hepatitis C virus and human immunodeficiency virus infections (De Clercq and Li [@CR27]). Jeon et al. ([@CR47]) have screened and identified two FDA-approved drugs such as niclosamide and ciclesonide against SARS-CoV-2. However, no structural based inhibitors against SARS-CoV-2 infection are not yet completed a clinical trial to date (Li et al. [@CR59]; Liu et al. [@CR65]; Xu et al. [@CR109]).

Helicase {#Sec12}
--------

SARS-CoV-2 helicase is an Mg^2+^-dependent enzyme with a zinc-binding domain in N-terminus displaying RNA and DNA duplex-unwinding activities with 5′--3′ polarity. The putative recombination patterns identified in helicase of SARS-CoV-2 are important for evolutionary survival allowing for genotype adjustment and adaptations in rapidly changing environments (Rehman et al. [@CR87]). Helicase is considered a better choice for the development of molecular diagnostic kits than antivirals (Chan et al. [@CR18]; Prajapat et al. [@CR123]).

Exoribonuclease {#Sec13}
---------------

The nonstructural protein Nsp15 encodes a nidoviral uridylate-specific endoribonuclease (NendoU). Like other coronaviruses, it plays an important role in viral infection and pathogenesis by interacting with the Nsp7/Nsp8 complex (Zhang et al. [@CR114]). The high-resolution crystal structure of endoribonuclease Nsp15/NendoU from SARS-CoV-2 was solved and described its catalytic domain and binding sites, which provide structural and functional evidence for developing antiviral drugs (Kim et al. [@CR53]).

2′-O-Methyltransferase {#Sec14}
----------------------

The nonstructural protein Nsp16 encodes cap-specific mRNA 2′-O-methyltransferase responsible for the RNA cap formation and methylation process of SARS-CoV-2. It binds to the N7-methyl guanosine cap and methylates the ribose 2′-O position of the first and second nucleotide of viral mRNA, which is essential to evade the immune system. Dolutegravir and bictegravir are important inhibitors of 2′-O-ribose methyltransferase identified by using molecular docking simulations (Khan et al. [@CR51]).

Envelope protein {#Sec15}
----------------

Envelope protein from SARS-CoV-2 acts as a viroporin and self-assembles in host membranes forming ion channels. Envelope protein plays a central role in virus morphogenesis and assembly. It also induces apoptosis and IL-1β overproduction in the host cells, leading to pathogenesis. The envelope protein of SARS-CoV-2 is evolutionarily conserved with higher gene expression efficiency in the hosts (Kandeel et al. [@CR49]; Zhou et al. [@CR119]). Generally, viral envelope proteins act as therapeutic targets for vaccine designing and engineering.

Nucleocapsid protein {#Sec16}
--------------------

The helical nucleocapsid interacts with spike, envelope, and membrane proteins to form the assembled virion (Zumla et al. [@CR121]). The N-terminal RNA-binding domain of nucleocapsid protein (PDB ID: 6M3M) was purified and the crystallographic structure solved for further target-based drug discovery (Fig. [3](#Fig3){ref-type="fig"}). The structure, as well as the function of this protein, was studied and then tested its interaction with various phytochemicals for identification suitable drug candidates (Gupta et al. [@CR42]). Still, more study on this target is needed for further drug discovery to treat COVID-19.

Development of anti-SARS-CoV-2 drugs {#Sec17}
====================================

Among therapeutic strategies, systemic corticosteroids and unselective or inappropriate administration of antibiotics for the treatment of COVID-19 are not recommended. There is no promising antiviral treatment is currently available. The WHO has approved several medications for the treatment of COVID-19 patients (Wang et al. [@CR103]) (Table [4](#Tab4){ref-type="table"}). They are: lopinavir/ritonavir, chloroquine, hydroxychloroquine, and α-interferon. The development of antivirals that specific to the SARS-CoV-2 is more effective for the current treatment of the COVID-19 pandemic. Molecular modeling studies have been predicted the protein's structures from SARS-CoV-2 and also identified numerous antivirals (Cortegiani et al. [@CR25]; Nabirotchkin et al. [@CR73]; Ghosh et al. [@CR37]). The constructed structural genomics and interactomics roadmaps could describe the molecular mechanisms behind the viral infection to design a vaccine or antivirals against COVID-19 (Srinivasan et al. [@CR97]). Current knowledge of the SARS-CoV-2 genomic information will thus advance the further development of anti-SARS-CoV-2 drugs.Table 4Anti-SARS-CoV-2 drugs and their mechanisms (approved by the World Health Organization on March 15, 2020)Approved drugCASMechanismRationale for useReferencesChloroquine54-05-7RdRp and ACE2 cellular receptor inhibitorPreclinical data on in vitro activity against SARS-CoV-2Gao et al. ([@CR35])Hydroxychloroquine118-42-3RdRp inhibitorPreclinical data on in vitro activity against SARS-CoV-2Wang et al. ([@CR103])Lopinavir; Ritonavir192725-17-0; 155213-67-5M^pro^ inhibitorAn open-label trial involving hospitalized patients with confirmed SARS-CoV-2Cao et al. ([@CR14])Remdesivir1809249-37-3RdRp inhibitorPreclinical data on in vitro activity against SARS-CoV-2Wang et al. ([@CR103])Azithromycin83905-01-5Downregulation of immune responses and cytokine productionPreclinical data on in vitro activity against SARS-CoV-2Arabi et al. ([@CR4])Tocilizumab375823-41-9IL-6 receptor inhibitorClinical data against SARS-CoV-2Xu et al. ([@CR108])COVID-19 convalescent plasma--Antibodies against SARS-CoV-2Clinical data against SARS-CoV-2FDA

Structure-based drug designing {#Sec18}
------------------------------

Conventional docking is a too computationally expensive and slow process for structure-based drug designing (Chellapandi and Prisilla [@CR20]; Prathiviraj et al. [@CR83]; Bharathi and Chellapandi [@CR10]; Prathiviraj and Chellapandi [@CR82]). To address this challenge, a deep docking platform has been developed for the accelerated screening of large chemical libraries, consisting of billions of entities (Liu et al. [@CR64]; Ton et al. [@CR99]). This platform utilizes quantitative structure--activity relationship models to screen out the top 1000 compounds targeting the main protease of which ZINC000541677852 predicted as a potent SARS-CoV-2 protease inhibitor (docking score −11.32 kcal/mol). Hydroxychloroquine is reported as a safe and effective drug against SARS-CoV-2 infection in vitro. Molecular docking combined with the physiologically based pharmacokinetic models has been used to identify its anti-SARS-CoV-2 activity (Yao et al. [@CR111]). Hydroxychloroquine can also significantly inhibit the main protease and also decrease the production of cytokines during SARS-CoV-2 infection (Kandeel and Al-Nazawi [@CR48]; Liu et al. [@CR63]). The crystal structures of SARS-CoV-2 main protease in complex with a SARS-CoV-inhibitor N3 and a potent broad-spectrum non-covalent inhibitor X77 were solved and deposited in the protein databank (PDB ID: 6LU7; 6W63). A docking view of the interaction between inhibitors (N3 and X77) and SARS-Cov-2 main protease is depicted in Fig. [4a](#Fig4){ref-type="fig"}.Fig. 43D structural view for the representation of SARS-CoV-2 target proteins in complex with main protease inhibitors (**a**) and human antibody CR3022 (**b**). The target protein is represented as a cartoon model (green) and inhibitors are represented as a ball and stick model

Structure-based vaccine designing {#Sec19}
---------------------------------

The structural and functional characterization of spike glycoprotein, polyprotein, envelope protein, and nucleocapsid protein is important for vaccine development. A crystal structure of the SARS-CoV-2 RBD in complex with human antibody CR3022 (PDB ID: 6W41) was solved recently, which guides vaccine designing or epitope engineering for COVID-19 (Fig. [4b](#Fig4){ref-type="fig"}). The immunoinformatics approach was used to identify significant cytotoxic T lymphocyte and B cell epitopes in the SARS-CoV-2 surface glycoprotein, which facilitates vaccine design of high priority (Baruah and Bose [@CR9]; Grifoni et al. [@CR40]). A similar approach has been applied to propose a specific synthetic vaccine epitope and peptidomimetic agent against SARS-CoV-2 based on the sequence motif KRSFIEDLLFNKV and surrounding variations (Robson [@CR89]).

Systems pharmacology for drug repurposing {#Sec20}
-----------------------------------------

Systems biology offers considerable promise in uncovering novel pathways by which microbial pathogens interact with host PPI networks to mediate disease severity (Chellapandi et al. [@CR21]; Murugan et al. [@CR72]; Prathiviraj and Chellapandi [@CR81]). Systems pharmacology attempts to model the effects of drug action by simultaneously modulating multiple proteins in a network. This approach can identify cellular antiviral targets from virus-host PPIs for the development of effective treatments for viral infections. The drug-gene-metabolism-disease network models are used to identify effective repurposable drugs and drug combinations for viral infections by quantification of the interplay between the virus-host interactome and drug targets in the human PPIs network. The potential drug combination is rationally predicted from the topological relationship between two drug-target modules that reflects biological and pharmacological relationships. The suitable drug targets and repurposed drugs are evaluated with molecular docking and validated with drug-induced gene signatures and virus-induced transcriptomics in human cell lines. Thus, drug repurposing comes into sight as a novel drug discovery process to yield efficient therapies against COVID-2019 rapidly due to time consuming, safety profiles, clinical trials, and FDA approvals of newly discovery drugs (Ahn et al. [@CR1]; Ke et al. [@CR50]; Tu et al. [@CR100]).

Several repurposed drugs have already been tested against COVID-2019 (Harrison [@CR43]). Systems pharmacology-based network medicine platform has been developed for the identification of disease-related genes, whether using genomic data and expression data or data directly collected from the scientific literature (Fu et al. [@CR34]; Zhou et al. [@CR120]). It is also used for the rapid identification of candidate repurposable drugs and potential drug combinations targeting SARS-CoV-2 using disease-related molecular networks. A systematic drug repurposing approach has been developed to identify promising inhibitors (Raltegravir, Paritaprevir, Bictegravir, and Dolutegravir) against 3C-like protease and 2′-O-ribose methyltransferase from SARS-CoV-2 (Khan et al. [@CR51]). The SCAR protocol has been developed to repurpose 6 covalent drugs targeting the main protease (3CLpro) of SARS-CoV-2 (Liu et al. [@CR64]). The proteomic-chemoinformatic approach has been developed for the detection of 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs or compounds being investigated (Gordon et al. [@CR39]).

Conclusions {#Sec21}
===========

The outbreak of COVID-19 poses a serious threat to global public health and local economies. The future evolution, adaptation, and spread of this virus warrant urgent investigation. It is imperative to discover affordable drugs to control and diminish the pandemic. The present review will provide new insights for those drugs currently ongoing clinical studies and also possible new strategies for drug designing or repositioning to treat SARS-CoV-2 infections. Compared to de novo drug discovery and randomized clinical trials, drug repurposing strategy could significantly shorten the time and reduce the cost of antiviral drugs. Nevertheless, experimental approaches for drug repurposing are costly and time consuming. It can be resolved by systems pharmacology approaches because targeting single virus proteins often has a high risk of drug resistance by the rapid evolution of virus genomes. Perhaps, the repositioning of launched or even failed drugs to viral diseases will provide unique translational opportunities. Genome-scale systems biological perspective of SARS-CoV-2-host interactions can guide the further in vitro and in vivo clinical studies on validation of newly identified drugs for COVID-19 infectivity. Genomic insights into developing and deploying drugs of antiviral drugs for COVID-19 will offer a substantially higher probability of success to the market and a significantly reduced cost and timeline to clinical availability. The currently established animal models are not very promising for the studies of pathogenesis and treatment of COVID-19 and therefore, testing the drugs for COVID-19 requires suitable animal models before their use in humans.
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